Abstract: Disclosed herein are methods, assemblies, systems, kits and devices for introducing molecules or compositions into cells or cell-like bodies. An assembly for introducing molecules in a solution into cells or cell-like bodies comprises a rigid container having a first inner diameter or cross-sectional area at a proximal end thereof and inner and outer walls extending between a distal and proximal end, a plunger insertable into the container at the proximal end, and at least one constriction of only the inner wall proximal to the distal end or at least one constriction of the inner and the outer walls proximal to the distal end, wherein the at least one constriction has a second inner diameter or cross-sectional area that is smaller than the container first inner diameter or cross-sectional area and the plunger is axially movable along the container.

Abstract: A method for rapidly determining effective sterilization, deimmunization, and/or disinfection of equipment and/or supplies by a device. The method includes providing a defined surrogate protein having a predetermined sequence representative of an infectious agent potentially contaminating the equipment and/or the supplies to be sterilized, deimmunized, and/or disinfected by the device. The defined surrogate protein having the predetermined sequence is subjected to sterilization, deimmunization, or disinfection. The effectiveness of the sterilization deimmunization, or disinfection is rapidly determined by determining if the defined surrogate protein has been destroyed.

Abstract: An assembly and method for processing human waste includes providing a supporting base having an opening within which a waste reservoir is affixed. The assembly may be installed on or below a rim of a toilet bowl. Solidification and pathogen killing materials are provided. The materials are deposited in the reservoir either prior to or upon accumulation of waste in the reservoir. The reservoir with the solidified waste is then sealed and transported to a collection facility.

Abstract: A system for sterilizing and/or deimmunizing an object includes a stationary chamber at ambient pressure configured to store an object to be sterilized and/or deimmunized therein. An electromagnetic device is coupled to the chamber and configured to direct microwaves at the object. A solvent spray subsystem is coupled to the chamber and configured to apply a solvent to the object such that the object is completely coated and/or saturated with the solvent. A controller subsystem coupled to the electromagnetic device and the solvent spray subsystem is configured to provide a cycle of activating the solvent spray subsystem for a predetermined amount of time, activating the electromagnetic device for a predetermined amount of time, and repeating the cycle a predetermined amount of times to irreversibly destroy proteins on the object to sterilize and/or deimmunize the object.

Abstract: A method for rapidly determining effective sterilization, deimmunization, and/or disinfection of equipment and/or supplies by a device. The method includes providing a defined surrogate protein having a predetermined sequence representative of an infectious agent potentially contaminating the equipment and/or the supplies to be sterilized, deimmunized, and/or disinfected by the device. The defined surrogate protein having the predetermined sequence is subjected to sterilization, deimmunization, or disinfection. The effectiveness of the sterilization deimmunization, or disinfection is rapidly determined by determining if the defined surrogate protein has been destroyed.

Abstract: A method for rapidly determining effective sterilization, deimmunization, and/or disinfection of equipment and/or supplies by a device. The method includes providing a defined surrogate protein having a predetermined sequence representative of an infectious agent potentially contaminating the equipment and/or the supplies to be sterilized, deimmunized, and/or disinfected by the device. The defined surrogate protein having the predetermined sequence is subjected to sterilization, deimmunization, or disinfection. The effectiveness of the sterilization deimmunization, or disinfection is rapidly determined by determining if the defined surrogate protein has been destroyed.

Abstract: A method for rapidly determining effective sterilization, deimmunization, and/or disinfection of equipment and/or supplies by a device. The method includes providing a defined surrogate protein having a predetermined sequence representative of an infectious agent potentially contaminating the equipment and/or the supplies to be sterilized, deimmunized, and/or disinfected by the device. The defined surrogate protein having the predetermined sequence is subjected to sterilization, deimmunization, or disinfection. The effectiveness of the sterilization deimmunization, or disinfection is rapidly determined by determining if the defined surrogate protein has been destroyed.

Abstract: A system for sterilizing and/or deimmunizing an object includes a stationary chamber at ambient pressure is configured to store an object to be sterilized and/or deimmunized therein. A solvent delivery subsystem is coupled to the chamber and configured to apply a directed volume of a non-toxic aqueous solvent to coat and wet the object to optimally hydrate proteins of infectious agents and/or immunological agents in or on the object for proteolysis. An electromagnetic device is coupled to the chamber and is configured to direct microwaves at the object to induce proteolysis of the proteins and generate heat to dry the non-toxic aqueous solvent in or on the object in or on the object. A temperature control subsystem is coupled to the chamber and is configured to control the temperature of the chamber to induce a temperature of the proteins which accelerates proteolysis of the proteins and dries the non-toxic aqueous solvent in or on the object.

Abstract: A method for rapidly determining effective sterilization, deimmunization, and/or disinfection of equipment and/or supplies by a device. The method includes providing a defined surrogate protein having a predetermined sequence representative of an infectious agent potentially contaminating the equipment and/or the supplies to be sterilized, deimmunized, and/or disinfected by the device. The defined surrogate protein having the predetermined sequence is subjected to sterilization, deimmunization, or disinfection. The effectiveness of the sterilization deimmunization, or disinfection is rapidly determined by determining if the defined surrogate protein has been destroyed.

Abstract: An assembly and method for processing human waste includes providing a supporting base having an opening within which a waste reservoir is affixed. The assembly may be installed on or below a rim of a toilet bowl. Solidification and pathogen killing materials are provided. The materials are deposited in the reservoir either prior to or upon accumulation of waste in the reservoir. The reservoir with the solidified waste is then sealed and transported to a collection facility.

Abstract: Waste containing a cytotoxic chemotherapy drug is collected in a container and contacted with a solidification material to form a solidified waste. The solidification material includes a mixture of an organic polymer and a Portland cement clinker. The organic polymer facilitating dispersal of the Portland cement clinker upon contacting said waste with the solidification material, wherein a volume of the solidified waste forms a stable matrix. The solidified waste is sealed within the container.

Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Abstract: A method for using a mixture of an organic polymer combined with an inorganic polymer is provided. When the mixture is combined with a liquid material, such as a urine from a patient that is contaminated with a dangerous cytotoxic drug, a multi-step process occurs that sequester the dangers. The combined material forms a stable matrix in which the cytotoxic chemotherapy drug is destroyed. Due to the combination of polymers, the multi-step process will occur without any mechanical mixing or stirring, as the organic polymer facilitates dispersal of the inorganic polymer through-out the combined material.

Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Abstract: An assembly and method for processing human waste includes providing a supporting base having an opening within which a waste reservoir is affixed. The assembly may be installed on or below a rim of a toilet bowl. Solidification and pathogen killing materials are provided. The materials are deposited in the reservoir either prior to or upon accumulation of waste in the reservoir. The reservoir with the solidified waste is then sealed and transported to a collection facility.

Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.

Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.